{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22523271",
  "DateCompleted": {
    "Year": "2012",
    "Month": "11",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2012",
        "Month": "04",
        "Day": "20"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1093/cid/cis430"
    ],
    "Journal": {
      "ISSN": "1537-6591",
      "JournalIssue": {
        "Volume": "55",
        "Issue": "3",
        "PubDate": {
          "Year": "2012",
          "Month": "Aug"
        }
      },
      "Title": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
      "ISOAbbreviation": "Clin Infect Dis"
    },
    "ArticleTitle": "Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.",
    "Pagination": {
      "StartPage": "351",
      "EndPage": "357",
      "MedlinePgn": "351-7"
    },
    "Abstract": {
      "AbstractText": [
        "An epidemic strain of Clostridium difficile designated by restriction endonuclease analysis (REA) as group BI has caused multiple outbreaks of severe C. difficile infection (CDI). The treatment response of patients infected with this strain is uncertain.",
        "Clostridium difficile isolates were collected from 2 phase 3 clinical trials comparing fidaxomicin to vancomycin and typed using REA. Clinical cure and recurrence outcomes were analyzed by strain type of the infecting organism, BI and non-BI, using both univariate and multivariate analyses.",
        "From 999 patients, 719 isolates were available for typing (356 fidaxomicin treated and 363 vancomycin treated). BI was the most common REA group (34% of isolates). Patients infected with BI had lower cure rates (86.6%; 214 of 247) than those infected with non-BI strains (94.3%; 445 of 472) (P < .001). The cure rate difference between the BI and non-BI patients was significant for both vancomycin (P = .02) and fidaxomicin (P = .007). BI patients had a recurrence rate of 27.4% (51 of 186), compared with a recurrence rate of 16.6% (66 of 397) in non-BI patients (P = .002). By multivariate analysis, BI infection was statistically significant as a risk factor for reduced cure (odds ratio [OR], 0.48; 95% confidence interval [CI], .27-.85; P = .030) and for increased recurrence (OR, 1.57; 95% CI, 1.01-2.45; P = .046).",
        "The clinical cure rate of patients infected with the epidemic BI C. difficile strain is lower than the cure rate of those infected with non-BI strains whether treated with fidaxomicin or vancomycin. Similarly, the CDI recurrence rate is increased in patients with the BI strain compared with patients with other C. difficile strains."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Edward Hines Jr VA Hospital, Hines, Illinois, USA. laurica.petrella@va.gov"
          }
        ],
        "LastName": "Petrella",
        "ForeName": "Laurica A",
        "Initials": "LA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sambol",
        "ForeName": "Susan P",
        "Initials": "SP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cheknis",
        "ForeName": "Adam",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nagaro",
        "ForeName": "Kristin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kean",
        "ForeName": "Yin",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sears",
        "ForeName": "Pamela S",
        "Initials": "PS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Babakhani",
        "ForeName": "Farah",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Johnson",
        "ForeName": "Stuart",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gerding",
        "ForeName": "Dale N",
        "Initials": "DN"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R44 AI063692",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Infect Dis",
    "NlmUniqueID": "9203213",
    "ISSNLinking": "1058-4838"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Aminoglycosides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "PHB2 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Prohibitins"
    },
    {
      "RegistryNumber": "6Q205EH1VU",
      "NameOfSubstance": "Vancomycin"
    },
    {
      "RegistryNumber": "Z5N076G8YQ",
      "NameOfSubstance": "Fidaxomicin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Aminoglycosides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "classification",
        "genetics",
        "isolation & purification",
        "pathogenicity"
      ],
      "DescriptorName": "Clostridioides difficile"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Clostridium Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Fidaxomicin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Typing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Polymorphism, Restriction Fragment Length"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prohibitins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recurrence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Vancomycin"
    }
  ]
}